Company Overview
Company Type: Public Company
Website: www.enveric.com
Number of Employees: 26
Ticker: ENVB (NasdaqCM)
Year Founded: -


Business Description
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
7.6
EBITDA
(28.5)
Total Enterprise Value
(2.1)
TEV/EBITDA
NM
EBIT
(29.0)
Cash & ST Invst.
9.7
P/Diluted EPS Before Extra
NM
Net Income
(30.5)
Total Debt
0.0
Price/Tang BV
1.2x
Capital Expenditure
0.0
Total Assets
13.5
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(2.65)
(1.70)
(11.70)
(4.92)
(7.21)
Revenue (mm)
0.00
0.00
0.00
0.00
0.00
EBITDA (mm)
-
-
(28.59)
(32.20)
(30.39)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/EBITDA
0.07x

Non-Periodic Estimates

Recommendation
Buy (1.00)
Target Price
11.68
Potential Upside
234.65%


Key Professionals
Name
Title
Tucker, Joseph Edward
CEO & Director
Coveney, Kevin M.
Chief Financial Officer
Facchini, Peter J.
Chief Innovation Officer

Key Board Members
Name
Title
Webb, Michael D.
Independent Chairman of the Board
Tucker, Joseph Edward
CEO & Director
Fava, Maurizio 
Chairman of Scientific Advisory Board
Kegler, George A.
Independent Non-Employee Director
Lind, Douglas D.
Independent Non-Employee Director
Pasqualone, Frank 
Independent Director
DeWitt, Sheila 
Member of Scientific Advisory Board
Krystal, John H.
Member of Scientific Advisory Board
Liebowitz, Michael B.
Member of Scientific Advisory Board
O'Neil, Bevin 
Independent Director
Schabacker, Marcus 
Independent Non-Employee Director
Stahl, Stephen M.
Member of Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
4851 Tamiami Trail N Suite 200 | Naples, FL | 34103 | United States
Phone: (239) 302-1707   

Current and Pending Investors
Armistice Capital LLC, Ayrton Capital LLC, Hudson Bay Capital Management LP, Intracoastal Capital LLC, Iroquois Capital Management, LLC, The Hewlett Fund, LP

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 3.26
Market Cap (mm)
7.6
Open
 3.85
Shares Out. (mm)
2.2
Previous Close
 3.49
Float %
92.0%
Change on Day
(0.23)
Shares Sold Short (mm)
0.0
Change % on Day
(6.7)%
Dividend Yield %
-
Day High/Low
 3.85/ 3.21
Diluted EPS Excl. Extra Items
(15.40)
52 wk High/Low
 9.59/ 1.79
P/Diluted EPS Before Extra
NM
Volume (mm)
0.03
Avg 3M Dly Vlm (mm)
0.09
Beta 5Y
0.21


 
Delayed Quote** | Last Updated on Oct-05-2023 02:22 PM (GMT-5)
NasdaqCM:ENVB - Common Stock


Index Membership
S&P Completion Index (CI);S&P TMI Index;S&P Completion Index (CI) Health Care (US Dollar);S&P TMI Health Care


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
MagicMed Industries Inc.
MagicMed Industries Inc. operates as a biotechnology company that develops psychedelic-derived medicinal and licit consumer goods products. It develops Psybrary, a molecular derivatives library that develops new patented products with a primary focus on psilocybin. The company was incorporated in 2020 and is based in Calgary, Canada.

United States and Canada
Biotechnology
-
-
-
Exclusive and perpetual licence for Diverse Biotech novel molecules
As of March 16, 2021, Exclusive and perpetual licence for Diverse Biotech novel molecules was acquired by Enveric Biosciences, Inc. Exclusive and perpetual licence for Diverse Biotech novel molecules comprises molecules to treat oncology and other debilitating diseases. The asset is located in the United States.

United States and Canada
Biotechnology
-
-
-
Ameri Holdings, Inc.
As of December 30, 2020,  Ameri Holdings, Inc. was acquired by Jay Pharma Inc., in a reverse merger transaction. Ameri Holdings, Inc., through its subsidiaries, provides SAP cloud, digital, and enterprise services worldwide. The company offers cloud services, including public, private, and hybrid cloud services, as well as SAP S/4 HANA, SAP SuccessFactors, and SAP Hybris cloud migration; and cloud automation solutions. It also provides digital services, such as Simple Advance Planning and Optimization mobile solution, a mobile application that offers sales professionals with real-time collaboration capabilities and customer data on their mobile devices; SAP IBP mobile app, which enables the real-time management and analysis of sales and operations planning related data from mobile devices; and robotic process automation that leverages the capability of artificially intelligent software agents for business process automation, as well as for reporting and analysis, and deliver insights into business functions by translating large data into structured reports. In addition, the company’s digital services comprise automating disparate and redundant data entry tasks by configuring software robots to integrate with existing software systems; and automating standard back office operations. Additionally, it designs, implements, and manages business intelligence and analytics solutions; generates instant financial reports and analytics of customer, product, and cost information; solutions for metadata repository, master data management, and data quality; and other enterprise services, such as consulting services for global and regional SAP implementations, as well as SAP/ information technology (IT) solution advisory and architectural, project management, IT/ enterprise resource planning (ERP) strategy, and vendor selection services. The company also offers data warehousing and other ERP services. Ameri Holdings, Inc. is headquartered in Suwanee, Georgia.

United States and Canada
IT Consulting and Other Services
21.00
14.00
6.00
Akos Biosciences, Inc.
Acanna Therapeutics, Inc. engages in developing cannabinoid medicines. The company was incorporated in 2022 and is based in Naples, Florida. Acanna Therapeutics, Inc. operates as a subsidiary of Enveric Biosciences, Inc..

United States and Canada
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-1-2023
-
Public Offering
Target
Enveric Biosciences, Inc. (NasdaqCM:ENVB)


2.39
Jan-20-2023
-
Shelf Registration
Target
Enveric Biosciences, Inc. (NasdaqCM:ENVB)


0.85
Aug-5-2022
Aug-11-2022
Shelf Registration
Target
Enveric Biosciences, Inc. (NasdaqCM:ENVB)

Armistice Capital, LLC (nka:Armistice Capital LLC),Intracoastal Capital LLC Seller Funds:Armistice Capital Master Fund Ltd.
10.93
Jul-25-2022
Jul-26-2022
Public Offering
Target
Enveric Biosciences, Inc. (NasdaqCM:ENVB)


3.00
Jul-22-2022
Jul-26-2022
Private Placement
Target
Enveric Biosciences, Inc. (NasdaqCM:ENVB)


5.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-18-2023
Company Conference Presentations
Enveric Biosciences, Inc. Presents at International Conference on Molecular Biology and Biochemistry 2023 (ICMBB 2023), Sep-18-2023
Sep-11-2023
Company Conference Presentations
Enveric Biosciences, Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-11-2023 07:00 AM
Sep-01-2023
Follow-on Equity Offerings
Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $2.392514 million.
Aug-21-2023
Product-Related Announcements
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
Jul-24-2023
Product-Related Announcements
Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

M&A Advisors
Fogler, Rubinoff LLP, Gemini Valuation Services, LLC, Haynes and Boone, LLP, Palladium Capital Group, LLC, Stikeman Elliott LLP, Torys LLP


Advisors
Most Recent Auditor
Marcum LLP
M&A Advisors
Fogler, Rubinoff LLP, Gemini Valuation Services, LLC, Haynes and Boone, LLP, Palladium Capital Group, LLC, Stikeman Elliott LLP, Torys LLP
Private Placement Advisors
H.C. Wainwright & Co., LLC
Public Offering Advisors
Dickinson Wright PLLC, H.C. Wainwright & Co., LLC, Haynes and Boone, LLP, Marcum LLP, Palladium Capital Group, LLC, Ram Associates


Most Recent Auditor
Marcum LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:29 AM
ENVB
Enveric Biosciences Inc 2023_10_05
Reports
14
CFRA Equity Research

Oct 01, 2023 11:48 AM
ENVB
Enveric Biosciences, Inc.
Reports
9
S&P Global Compustat

Sep 07, 2023 03:16 AM
ENVB
Enveric Biosciences Inc 2023_09_07
Reports
14
ValuEngine, Inc.

Sep 01, 2023 02:50 AM
ENVB
ValuEngine Rating and Forecast Report for ENVB
Reports
11
Alliance Global Partners
Molloy, James Francis
Aug 31, 2023 05:05 AM
ENVB
ENVB continues to advance towards their initial IND filing in 2024
Ratings Change*
8
Diamond Equity Research LLC
Diamond, Hunter Louis
Aug 24, 2023 09:11 AM
ENVB
ENVB: Translating Psychedelics Science and AI into Breakthrough Therapies for Debilitating CNS Disorders
Initiation of Coverage*
24
Pechala's Reports

Aug 04, 2023 11:00 PM
ENVB
ENVERIC BIOSCIENCES INC COMMON (ENVB=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS
Reports
2
Alliance Global Partners
Molloy, James Francis
Jul 13, 2023 05:05 AM
ENVB
ENVB positioning itself to lead the psilocybin revolution in neurology treatments
Initiation of Coverage*
8
S&P Global Compustat

Jul 06, 2023 02:52 AM
ENVB
Enveric Biosciences Inc 2023_07_06
Reports
14
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jul 02, 2023 06:00 PM
ENVB
Rating Update for Enveric Biosciences Inc
EPS Estimates*
3


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


AdvisorShares Investments, LLC

100,429

4.60

0.4

Jun-30-2023


Intracoastal Capital LLC

81,136

3.72

0.3

Dec-31-2022


Alpha Capital Anstalt

47,028

2.16

0.2

Dec-31-2022


Kanubaddi, Avani V.

37,068

1.70

0.1

Aug-01-2023


BlackRock, Inc.

29,578

1.36

0.1

Jun-30-2023


Renaissance Technologies LLC

17,170

0.79

0.1

Jun-30-2023


Tucker Ph.D., Joseph Edward

16,040

0.74

0.1

Aug-01-2023


Hagel Ph.D., Jillian Marie

15,422

0.71

0.1

Jan-25-2023


Citadel Advisors LLC

13,933

0.64

0.1

Jun-30-2023


Facchini Ph.D., Peter J.

13,902

0.64

0.1

Aug-01-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Kanubaddi, Avani V.
37,068
37,068
Renaissance Technologies LLC
17,170
17,170
Citadel Advisors LLC
13,933
13,933
Acadian Asset Management LLC
4,559
4,559
Tucker Ph.D., Joseph Edward
16,040
2,218

Top Sellers
Sellers
Common Stock Equivalent Held
Change
AdvisorShares Investments, LLC
100,429
(42,587)
Susquehanna International Group, LLP, Asset Management Arm
0
(12,481)
Virtu Financial LLC, Asset Management Arm
0
(10,683)
Tower Research Capital LLC
8,327
(5,802)
UBS Asset Management AG
54
(5,264)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-12
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
ENP Newswire
Sep-08
Elite Pharmaceuticals Appoints Carter Ward as Chief Financial Officer
India Pharma News
Sep-06
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
ENP Newswire
Sep-05
Enveric Biosciences to Raise Up to USD2.39 Million in Public Offering of Shares
Marketline - Deals


Company Coverage
This company is not on any Coverage List.

Products
Bioproduction Platform, Cannabinoid and COX-2 inhibitor Conjugation (Future), Cannabinoid-Infused Topical Product (Future), EB-373 (Future), EV101 (Future), EV102 (Future), EV104 (Future), EVM-101 (Future), EVM-201 (Future), EVM-301 (Future)


Upcoming Events
Date/Time
Type
Nov-02-2023 10:00 AM (EST)
Shareholder/Analyst Calls
Nov-02-2023
Annual General Meeting
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-03-2023
Oct-03-2023
Enveric Biosciences, Inc. (NasdaqCM:ENVB)
SEC
8-K (7.01, 9.01)
239 KB
Sep-27-2023
Sep-27-2023
Enveric Biosciences, Inc. (NasdaqCM:ENVB)
SEC
8-K (7.01, 9.01)
239 KB
Sep-20-2023
Sep-20-2023
Enveric Biosciences, Inc. (NasdaqCM:ENVB)
SEC
8-K (7.01, 9.01)
241 KB
Sep-18-2023
-
Enveric Biosciences, Inc. (NasdaqCM:ENVB)
SEC
DEFA14A
2 MB
Sep-18-2023
Sep-18-2023
Enveric Biosciences, Inc. (NasdaqCM:ENVB)
SEC
DEF 14A
2 MB
Sep-18-2023
Sep-18-2023
Enveric Biosciences, Inc. (NasdaqCM:ENVB)
SEC
8-K (7.01, 9.01)
256 KB
Sep-11-2023
Sep-11-2023
Enveric Biosciences, Inc. (NasdaqCM:ENVB)
SEC
8-K (7.01, 9.01)
239 KB
Sep-07-2023
Sep-07-2023
Enveric Biosciences, Inc. (NasdaqCM:ENVB)
SEC
PRE 14A
2 MB
Sep-05-2023
Sep-05-2023
Enveric Biosciences, Inc. (NasdaqCM:ENVB)
SEC
8-K (7.01, 9.01)
244 KB
Sep-01-2023
-
Enveric Biosciences, Inc. (NasdaqCM:ENVB)
SEC
424B5
405 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Pasqualone, Frank  (Independent Director)
Sep-15-2023
Ordinary Shares
1,000
2,940
Open Market Acquisition
New
Form 4
Coveney CPA, Kevin M. (Chief Financial Officer)
Mar-13-2023
restricted stock units
26,500
0
Other Acquisition
New
Form 4
Kanubaddi, Avani V. (Former President & COO)
Jan-25-2023
Ordinary Shares
10,000
0
Other Acquisition
26.08
Form 4
Tucker Ph.D., Joseph Edward (CEO & Director)
Jan-25-2023
RSU
44,000
0
Other Acquisition
377.52
Form 4
Facchini Ph.D., Peter J. (Chief Innovation Officer)
Jan-25-2023
restricted stock units
17,000
0
Other Acquisition
213.89
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Webb, Michael D.
Independent Chairman of the Board
(239) 302-1707
-

Tucker, Joseph Edward
CEO & Director
(239) 302-1707
-
jtucker@magicmedindustries.com
Fava, Maurizio 
Chairman of Scientific Advisory Board
(239) 302-1707
-

Kegler, George A.
Independent Non-Employee Director
(239) 302-1707
-

Lind, Douglas D.
Independent Non-Employee Director
(239) 302-1707
-

Pasqualone, Frank 
Independent Director
(239) 302-1707
-

DeWitt, Sheila 
Member of Scientific Advisory Board
(239) 302-1707
-

Krystal, John H.
Member of Scientific Advisory Board
(239) 302-1707
-

Liebowitz, Michael B.
Member of Scientific Advisory Board
(239) 302-1707
-

O'Neil, Bevin 
Independent Director
(239) 302-1707
-

Schabacker, Marcus 
Independent Non-Employee Director
(239) 302-1707
-

Stahl, Stephen M.
Member of Scientific Advisory Board
(239) 302-1707
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Tucker, Joseph Edward
CEO & Director
(239) 302-1707
-
jtucker@magicmedindustries.com
Coveney, Kevin M.
Chief Financial Officer
(239) 302-1707
-

Facchini, Peter J.
Chief Innovation Officer
(239) 302-1707
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
